CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,179 enrolled
Drug / intervention
Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00759148
NCT00759148Phase 3Completed
CompareCT.gov

Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis

Alcon Research·interventional·Posted Sep 25, 2008·Updated Jan 2, 2018

In Brief

A Phase 3 clinical trial evaluating Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5% and Moxifloxacin AF Vehicle for Bacterial Conjunctivitis. Completed, enrolled 1,179 participants.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of Moxifloxacin AF Ophthalmic Solution compared to Moxifloxacin AF Vehicle in the treatment of bacterial conjunctivitis in patients one month of age or older.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Conjunctivitis
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 25, 2008
Enrollment StartOct 1, 2008
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 17.8 years ago

Interventions

Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%drug

Eye drops

Moxifloxacin AF Vehicleother

Inactive ingredients used as a placebo for masking purposes